CACNA1H
ENSG00000196557
Target class
Ion channel
Chromosome
16
Approved drugs
12
Clinical candidates (approved and in development)
18
- Approved drugs
- 12
- Clinical candidates (approved and in development)
- 18
- Chemical probe available
- Yes
- Other names
- Cav3.2
- Target name
- CACNA1H
- Gene name
- Calcium voltage-gated channel subunit alpha1 H
- Gene symbol
- CACNA1H
- Protein name
- Voltage-dependent T-type calcium channel subunit alpha-1H (Low-voltage-activated calcium channel alpha1 3.2 subunit) (Voltage-gated calcium channel subunit alpha Cav3.2)
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 50
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 212.68
- Tissue specificity (Gini)
- 0.641
- Tissue specificity (tau)
- 0.832
- KEGG gene identifiers
- hsa:8912
- Protein interaction confidence
- 0.81725
- Protein interaction partners
- 68
- R-HSA-419037
- R-HSA-445355
- R-HSA-9856532
- End position
- 1224169
- Start position
- 1153103
- Chromosome
- 16
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Note=Interaction with STAC increases expression at the cell membrane. .
- Nucleoplasm
- Vesicles
- PubMed 25907736
- PubMed 27149520
- PubMed 27729216
- PubMed 9670923
- PubMed 9930755
- Tissue specificity (tau)
- 0.832165
- Expression inequality (Gini)
- 0.641014
Expression in transcripts per million
- Colon - Sigmoid
- 212.68
- Esophagus - Muscularis
- 190.76
- Ovary
- 175.42
- Esophagus - Gastroesophageal Junction
- 158.57
- Uterus
- 130.32
Expression in transcripts per million
- Colon - Sigmoid212.68
- Esophagus - Muscularis190.76
- Ovary175.42
- Esophagus - Gastroesophageal Junction158.57
- Uterus130.32
- Bladder128.92
- Artery - Tibial114.56
- Pituitary107.39
- Fallopian Tube86.6
- Cervix - Endocervix71.11
- Cervix - Ectocervix66.45
- Artery - Coronary65.95
- Prostate60.12
- Colon - Transverse57.58
- Testis48.03
- Adrenal Gland30.4
- Skin - Sun Exposed (Lower leg)29.18
- Vagina27.47
- Thyroid25.02
- Lung24.49
- Adipose - Subcutaneous22.84
- Kidney - Medulla20.41
- Brain - Nucleus accumbens (basal ganglia)18.95
- Brain - Caudate (basal ganglia)18.77
- Brain - Putamen (basal ganglia)16.63
And 29 more, listed on the interactive page.
- GO:0006936
- GO:0007520
- GO:0008016
- GO:0032342
- GO:0032870
- GO:0034651
- GO:0035865
- GO:0042391
- GO:0055085
- GO:0070509
- GO:2000344
- GO:0005886
- GO:0005891
- GO:0016020
- GO:0005244
- GO:0005245
- GO:0005515
- GO:0008332
- GO:0097110
Related records
Trials (1,036)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (21)
- ABT-639 Voltage-gated T-type calcium channel alpha-1H subunit blocker
- Apinocaltamide Voltage-gated T-type calcium channel blocker
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Ethosuximide Voltage-gated T-type calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Methsuximide Voltage-gated T-type calcium channel blocker
- Mibefradil Voltage-gated T-type calcium channel blocker
- Mibefradil dihydrochloride Voltage-gated T-type calcium channel blocker
- Paramethadione Voltage-gated T-type calcium channel blocker
- Phensuximide Voltage-gated T-type calcium channel blocker
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Suvecaltamide Voltage-gated T-type calcium channel modulator
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker